Clinical Trial Update: Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating repeat-dose infusions of Forodesine Hydrochloride (BCX-1777) in patients with advanced T-cell leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia

Drugs mentioned

• Forodesine hydrochloride (forodesine hydrochloride)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Leukemia, T-Cell | Phase 2 | Status: COMPLETED